Stevanato Group (NYSE:STVN – Get Free Report) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Profitability
This table compares Stevanato Group and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stevanato Group | 11.99% | 10.52% | 6.32% |
| Kiora Pharmaceuticals | N/A | -36.35% | -25.82% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Stevanato Group and Kiora Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stevanato Group | 0 | 3 | 1 | 1 | 2.60 |
| Kiora Pharmaceuticals | 1 | 1 | 1 | 0 | 2.00 |
Valuation & Earnings
This table compares Stevanato Group and Kiora Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stevanato Group | $1.19 billion | 3.93 | $127.45 million | €0.57 | 27.18 |
| Kiora Pharmaceuticals | $16.02 million | 0.49 | $3.60 million | ($2.09) | -1.03 |
Stevanato Group has higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Stevanato Group has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.82, indicating that its stock price is 182% less volatile than the S&P 500.
Summary
Stevanato Group beats Kiora Pharmaceuticals on 11 of the 14 factors compared between the two stocks.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
